



FOR IMMEDIATE RELEASE
May 11, 2015

Media Contact:
Molly Stewart, Pennsylvania Bio
Phone: 610.947.6800 ext. 211

Pennsylvania Bio Announces Chairman-Elect and New Board Members
Appointments Reflect Diversity of the Association's Membership

WAYNE, PA – Pennsylvania Bio, the statewide trade association representing the commonwealth's life sciences industry, announced today the appointment of Marc S. Malandro, PhD, CLP, RTTP as chairman-elect of the association. Dr. Malandro is the Founding Director of the University of Pittsburgh's Innovation Institute and Associate Vice Chancellor for Technology Management and Commercialization at the University of Pittsburgh. He will assume the position of chairman at the January 2016 meeting of the Pennsylvania Bio Board of Directors.

The association also announced the election of nine new members to its Board of Directors:

- **Neil J. Campbell**
President, CEO and Founder, Helomics Corporation
- **Christopher M. Cashman**
President and CEO, Marinus Pharmaceuticals
- **Glen N. Gaulton, Ph.D.**
Executive Vice Dean and Chief Scientific Officer, Perelman School of Medicine,
University of Pennsylvania
- **Maxine Gowen, Ph.D.**
President and CEO, Trevena
- **Mahmood Ladha**
VP, US Business Development Operations, Head of Transactions, AstraZeneca
- **Terri J. Lee**
Vice President, State Government Affairs & Policy, Merck
- **Christian Manders**
Chief Operating Officer, Promethean LifeSciences, Inc.
- **Robert Radie**
President and Chief Executive Officer, Egalet Corporation
- **Dr. Neal Walker**
President and CEO, Aclaris Therapeutics

“On behalf of the Pennsylvania Bio Board of Directors, we are honored to introduce Dr. Malandro’s term as chairman-elect and welcome nine industry leaders whose expertise and leadership will be essential assets to the Board of Directors and the Association,” said Robert Bazemore, Chairman of the Pennsylvania Bio Board of Directors and Chief Operating Officer, Synageva BioPharma Corp. “Under Marc’s leadership and guidance, we are confident the association will continue to set new standards for state association advocacy effectiveness and member value.”

“Marc is a valued leader, coach and supporter of Pennsylvania Bio. His election as chairman will further strengthen the ties between the med-tech powerhouse of Western Pennsylvania and the global biopharma leadership role of the Southeast, unifying the entire ecosystem of the commonwealth as, together, we position Pennsylvania as the most attractive place in the United States to open and operate a life sciences company,” added Pennsylvania Bio president and CEO Christopher Molineaux. “Moreover, the addition of these nine exceptional individuals to the Board continues our ongoing effort as a trade association to ensure Pennsylvania remains a global leader in the life sciences industry.”

About the New Pennsylvania Bio Board Members

Neil Campbell is currently the President, CEO and Founder of Helomics, a Pittsburgh-based personalized healthcare company in oncology commercializing comprehensive tumor profiling. Neil also serves as Industry Advisor and Operating Partner for Healthcare Royalty Partners, a multi-billion dollar private equity fund in the healthcare sectors. Neil has been an active member of the Scottish government’s Global Scots and the Beachheads Advisory Council of the New Zealand/Australian government science & technology agency since its inception and serves as Executive Chairman for Mosaigen® Corporation, Founder and Chairman of KidsRgenius®, and also volunteers as Chairman for Child Health Research Institute, (CureKids™). Formerly, Mr. Campbell was President and CEO, Co-Founder of SuperNova Diagnostics®, Inc, a private global diagnostics company with a proprietary platform for conducting point-of-care diagnostics. Neil has also served as General Partner for Endeavour Capital; President & COO/CEO for EntreMed Pharmaceuticals; and Senior Director of Commercial Development for Celera Genomics. Additionally, Mr. Campbell has held General & Executive Management positions at Life Technologies, Inc., IGEN, Inc., acquired by Roche, and Abbott Laboratories. Neil is in the final stages of pursuing a Doctorate from the University of Liverpool in the United Kingdom and earned his M.B.A. and M.A. from Webster University and his B.S.-B.A. from Norwich University in the United States.

Chris Cashman is President and CEO of Marinus (NASDAQ: MRNS) and also serves as Chairman of the Marinus Board of Directors. Chris is a recognized leader in the biopharmaceutical industry and has decades of experience leading life sciences companies. Prior to joining Marinus, Chris was co-founder, President and CEO of Protez Pharmaceuticals, Inc., a company specializing in the development of antibiotics, which was acquired by Novartis. Prior to his time with Protez, Chris was President and CEO of Message Pharmaceuticals Inc., and held various leadership roles at both Pfizer Inc. and SmithKline Beecham plc. Chris currently serves on the board of directors of Rapid Micro Biosystems, Inc., Noble Biomaterials, Inc. and MBF Therapeutics Inc. Chris holds an M.S. in Economics from Purdue University and B.S. in Business Management from the University of Minnesota.

Glen N. Gaulton, Ph.D. is the Executive Vice Dean and Chief Scientific Officer, and Professor of Pathology and Laboratory of Medicine at the University of Pennsylvania’s Perelman School of Medicine. Dr. Gaulton received his Ph.D. in biochemistry and molecular biology from the University of California, Santa Barbara. He conducted postgraduate research in immunology at the School of Public Health and the School of Medicine at Harvard University. In 1985, Dr. Gaulton joined the faculty of the Pathology and Laboratory Medicine department in the School of Medicine at the University of Pennsylvania where he is currently full professor. Dr. Gaulton’s research is focused in the areas of immunology and virus

pathogenesis, where he has published over 100 manuscripts and texts, and directly supervised the research training of thirty three graduate students and fellows. Dr. Gaulton serves on the Board of Directors of three organizations, is a reviewer/editor for nine scholarly journals, and has been chair of four NIH study sections. Dr. Gaulton has held numerous administrative roles at Penn, including Director of the Combined Degree and Physician Scholar Programs, Director of Biomedical Graduate Studies, and Vice Dean for Research and Research Training. In his current role as CSO/EVD Dr. Gaulton sets and implements the strategic direction for research at the Perelman School of Medicine.

Dr. Maxine Gowen is the founding President and CEO of Trevena (NASDAQ: TRVN). Prior to Trevena Dr. Gowen held a variety of leadership roles at GlaxoSmithKline (GSK) over a period of fifteen years. As Senior Vice President for the Center of Excellence for External Drug Discovery (CEEDD), she developed an innovative new approach to externalizing drug discovery in big pharma. Dr. Gowen was previously President and Managing Partner at SR One, the venture capital subsidiary of GSK, where she led its investments in, and served on the board of, directors of numerous companies. Until 2002 Dr. Gowen was Vice President, Drug Discovery, Musculoskeletal Diseases at GSK, responsible for drug discovery and early development for osteoporosis, arthritis and metastatic bone disease. Dr. Gowen held a tenured academic position in the School of Pharmacology, University of Bath, UK from 1989-1992. She has authored more than 100 refereed scientific publications. Dr. Gowen graduated with a B.Sc. in biochemistry from the University of Bristol, UK, received a Ph.D. in cell biology from the University of Sheffield, UK, and received an MBA from the Wharton School of the University of Pennsylvania. Dr. Gowen serves on the Board of Directors of Akebia Therapeutics (AKBA) and of the biotechnology industry association, BIO.

Mahmood Ladha has over 22 years of industry experience both on the pharma and service side. In his current role as VP and Head of Transactions based in the US, he is accountable for completing a variety of transactions for AstraZeneca (NYSE: AZN) across therapeutic areas and across assets in any phase of development. In addition to a variety of licenses, divestments and collaborations, Mahmood led the public company acquisitions of Ardea and Omthera and most recently the acquisition of the respiratory assets of Actavis this year. He began his career in sales and sales management moving into progressive executive marketing roles. As head of AstraZeneca's respiratory marketing in the U.S., he launched Pulmicort Respules, Rhinocort Aqua, and Accolate Peds. During his time with Innovex as the COO, Mahmood led the transition of the organization from one that delivered large, primary care sales forces to a provider of a variety of field selling services including specialty sales and medical sales liaisons.

Terri Lee is Vice President of State Government Affairs and Policy for Merck & Co., Inc. (NYSE: MRK), and is based in North Wales, PA. In this capacity she directs the company's interactions with state elected and appointed officials and governmental entities, and leads a team of government affairs and policy professionals across the states. With more than 20 years of public policy experience she has successfully led numerous initiatives to support innovative discovery and research within the life sciences industry. In addition to representing Merck on a number of national industry and state legislative and policy organizations, she was most recently elected Vice Chair for the State Section of the Pharmaceutical Research and Manufacturers of America (PhRMA). Since joining Merck in 1987 she has held positions in sales, recruiting and development, and policy. She was honored as one of Merck's Most Amazing Women, and was one of five employees worldwide to receive the One Merck Diversity and Inclusion Award for her work with external partners. She was also recently presented the NBCSL Corporate Achievement Award for Partnership & Social Responsibility having served four years as Chair of their Corporate Roundtable, and was recognized by the Healthcare Business Women's Association, both for her work to protect public interest and promote public health policy.

Christian Manders is the Chief Operating Officer of Promethean Life Sciences, a Pittsburgh-based biomedical company specializing in the development of reconstructive surgery products. Mr. Manders grew up in Hershey, PA and attended Yale University, where he majored in history. Upon graduation, he moved to Pittsburgh to join his family with the hopes of commercializing his father's intellectual property. Promethean LifeSciences is the result. At Promethean, Mr. Manders is responsible for overseeing the daily operations of the company. He has successfully gained FDA approval for their products, GammaGraft and Repriza, human skin allograft products for the treatment of wounds and reconstructive procedures. Promethean is currently marketing GammaGraft and Repriza in the US. Promethean is commercializing a variety of surgical products in a range of medical specialties. He has served on the Board of Governors of the American Association of Tissue Banks, helps organize the Pittsburgh Biomedical Breakfasts, and is active in the life sciences community in Pittsburgh.

Robert Radie is President and CEO and a member of the Board of Directors at Egalet Corporation (NASDAQ: EGLT). From November 2010 to October 2011, Mr. Radie served as President and CEO of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur in 2011. From March 2009 to November 2010, Mr. Radie served as President and CEO of Transmolecular, Inc., a biotechnology company developing cancer diagnostic and treatment products, after serving as a consultant to Transmolecular from December 2008 through March 2009. From September 2007 to September 2008, Mr. Radie served as the Chief Business Officer of Prestwick Pharmaceuticals, Inc., a specialty pharmaceutical company. Before joining Prestwick, Mr. Radie served in senior management positions with a number of pharmaceutical and biotechnology companies, including Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and Eli Lilly and Company. Mr. Radie serves as a director of Paratek Pharmaceuticals, a biopharmaceutical company, and Horse Power for Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer. Mr. Radie received his B.S. in chemistry from Boston College.

Dr. Neal Walker is co-founder, President and Chief Executive Officer at Aclaris Therapeutics, Inc. He is also a co-founding member of Nexeption, LLC, a biopharmaceutical assets management company. Dr. Walker is a board certified dermatologist and serial entrepreneur with over 18 years of experience in the biopharmaceutical industry. Prior to founding Aclaris, Dr. Walker was co-founder, President and Chief Executive Officer of Vicept Therapeutics, Inc., a dermatology-focused specialty pharmaceutical company (acquired by Allergan). Dr. Walker began his pharmaceutical industry career at Johnson and Johnson and has co-founded and led a number of life science companies: Octagon Research Solutions, a software and services provider to biopharmaceutical companies (acquired by Accenture); Trigenesis Therapeutics, Inc., a specialty dermatology company where he served as Chief Medical Officer (acquired by Dr. Reddy's Laboratories, Inc.); and Cutix, Inc., a commercial dermatology company. Dr. Walker co-founded and is Vice Chairman of Alexar Therapeutics, Inc. and serves on the Board of Directors of Sebacia, Inc. He also co-founded and serves on the Board of Directors of the Dermatology Summit, an Advancing Innovation in Dermatology Conference. He previously served on the Board of Directors for Octagon and the Advisory Board of Flexible Medical Systems. Dr. Walker received his MBA from The Wharton School, University of Pennsylvania.

About Pennsylvania Bio

Pennsylvania Bio is the statewide trade association for the life sciences in Pennsylvania and serves as a catalyst to ensure Pennsylvania is a global leader in the life sciences by developing a business and public policy environment which fosters life science growth and success. <http://www.pabio.org>.